Limitations of this study include the single-centre setting, the predominance of a single cancer type (lung cancer), the paucity of anti-CTLA4 cases and the inherent challenges of clinically diagnosing and characterising many irAEs. The gene discussed is CTLA4; the disease is lung cancer.